


**Product Name** : MJN110  
**Cat. No.** : PC-60707  
**CAS No.** : 1438416-21-7  
**Molecular Formula** : C<sub>22</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>4</sub>  
**Molecular Weight** : 462.327  
**Target** : Monoacylglycerol Lipase (MAGL)  
**Solubility** : 10 mM in DMSO



## Biological Activity

MJN110 (MJN-110) is a potent, selective, and orally active **MAGL inhibitor** with IC<sub>50</sub> of 2.1 nM (2-AG hydrolysis). MJN110 weakly inhibits ABHD6, with excellent selectivity over FAAH and other serine hydrolases. MJN110 inactivates hMAGL with IC<sub>50</sub> of 9.1 nM, attenuates established mechanical allodynia in rat model of diabetic neuropathy.

## References

- Niphakis MJ, et al. *ACS Chem Neurosci*. 2013 Sep 18;4(9):1322-32.  
Parker LA, et al. *Psychopharmacology (Berl)*. 2015 Feb;232(3):583-93.  
Ignatowska-Jankowska B, *J Pharmacol Exp Ther*. 2015 May;353(2):424-32. et al.  
Wilkerson JL, et al. *J Pharmacol Exp Ther*. 2016 Apr;357(1):145-56.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com